Adamas To Present Analysis of Clinical Trials on GOCOVRI® Treatment at the 3rd Pan American Parkinson’s Disease and Moveme...
February 13 2020 - 9:00AM
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to
developing and delivering medicines that make a clinically
meaningful difference to people affected by neurological diseases,
announced today two presentations on GOCOVRI® (amantadine) extended
release capsules for the treatment of dyskinesia in people with
Parkinson's disease (PD) receiving levodopa-based therapy at the
3rd Pan American Parkinson’s Disease and Movement Disorders
Congress (PAS-MDS), February 14-16, 2020 in Miami, Florida.
“The data presented at this year’s MDS-PAS
conference build upon the growing evidence that GOCOVRI can help
improve good ON time in patients with PD who experience
levodopa-induced dyskinesia,” said Jean Hubble, Vice President,
Medical Affairs at Adamas. “We are proud to present clinical
results that suggest GOCOVRI may provide additional treatment
benefit for people with Parkinson’s who have an insufficient
response to deep brain stimulation, amantadine immediate release,
or both – providing patients with more good ON time, with less
troublesome dyskinesia and reduced OFF time.”
The posters will be presented during the
dyskinesia poster session taking place in the Biscayne Ballroom at
the InterContinental Miami Hotel on Friday, February 14, from 1:00
pm to 2:30pm Eastern Standard Time. Details of the poster
presentations are as follows:
|
Poster 54:
“Reduced Dyskinesia and OFF time in PD Patients with DBS Following
Switch from Amantadine IR to GOCOVRI (Amantadine) Extended Release
Capsules: Analysis of 2-Year Open-Label Trial (EASE LID 2)”Lead
author: Caroline M. Tanner, MD, PhD, University of California San
Francisco |
|
|
|
Poster 55: “PD Patient Diaries Demonstrated GOCOVRI
(Amantadine) Extended Release Capsules Improved ON Time without
Dyskinesia: Results from Pooled Phase 3 Clinical Trials”Lead
author: Robert A. Hauser, MD, University of South Florida |
About Parkinson’s Disease, Dyskinesia
and OFFParkinson’s Disease (PD) is a progressive,
neurodegenerative disorder caused by the gradual loss of brain
cells that produce the neurotransmitter dopamine and affects
approximately one million people in the United States. Dopamine
decline in the brain results in a wide range of motor
(movement-related) and non-motor symptoms. As the disease
progresses, people are likely to experience unpredictable
stiffness, rigidity and tremors, referred to as OFF time. The
primary treatment for PD is with levodopa; however, over time
levodopa may lead to involuntary, uncontrolled movements known as
dyskinesia. The abrupt and unpredictable transitions between
episodes of dyskinesia, normal movement and OFF time lead to
considerable impact on patients’ lives.
About GOCOVRI®
GOCOVRI® (amantadine) extended-release capsules is the first
and only FDA-approved medicine indicated for the treatment of
dyskinesia in patients with Parkinson’s disease receiving
levodopa-based therapy, with or without concomitant dopaminergic
medications. It is also the only medicine clinically proven to
reduce both dyskinesia and OFF.
Taken once daily at bedtime, GOCOVRI provides an
initial lag and a slow rise in amantadine concentration during the
night, resulting in a high concentration from the morning and
throughout the waking day. Additionally, in the clinical trials,
the adjunctive use of GOCOVRI did not require dose changes to
dopaminergic therapies. The most commonly observed adverse
reactions with GOCOVRI were hallucinations, dizziness, dry mouth,
peripheral edema, constipation, falls and orthostatic
hypotension.
For more information about GOCOVRI, please visit
www.GOCOVRI.com.
About Adamas Pharmaceuticals,
Inc.At Adamas, our purpose and vision are clear: deliver
innovative medicines that make a clinically meaningful difference
for patients, caregivers and society. We are a fully-integrated
company focused on growing a portfolio of therapies to address a
range of neurological diseases. For more information, please
visit www.adamaspharma.com.
Forward-looking
statementsStatements contained in this press release
regarding matters that may occur in the future, including the
expectations as to the long-term benefits of GOCOVRI, are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to risks and uncertainties, and actual results may differ
materially from those expressed or implied by such forward-looking
statements. For a description of risks and uncertainties that could
cause actual results to differ from those expressed in
forward-looking statements, including risks relating to Adamas’
commercial activities relating to GOCOVRI, and the regulatory and
competitive environment and Adamas’ business in general, see
Adamas’ Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on November 7, 2019, particularly under the
caption “Risk Factors.” Investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this release. Adamas undertakes no obligation to
update any forward-looking statement in this press release, except
as required by law.
Contact:
Investors:Peter VozzoManaging Director,
Westwicke443-213-0505peter.vozzo@westwicke.com
Media:Sarah MathiesonVice President of Corporate
Communications510-450-3528smathieson@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2024 to Jun 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jun 2023 to Jun 2024